🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB

Recruitingn/aAges 18 Years - anyFemaleSun Yat-sen University
NCT06781151 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a non-interventional, real-world study divided into two parts: a retrospective study and a prospective study. The main question it aims to answer is: Will genomic sequencing and molecular tumor boards lead to clinical responses in patients with recurrent ovarian, cervical, or endometrial cancer? The retrospective arm will analyze data from patients with recurrent gynecological malignancies (ovarian, cervical, or endometrial) who underwent multidisciplinary consultations at our institution from January 2022 onward. Data collected will include tumor tissue genomic sequencing results, medical histories, multidisciplinary consultation recommendations, and subsequent treatment courses. This analysis will examine the implementation and clinical efficacy of personalized targeted therapies guided by molecular tumor profiling and multidisciplinary consultation. The prospective arm will

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with recurrent ovarian, cervical, or endometrial cancer referred for multidisciplinary consultation by a gynecological oncologist; * Presence of at least one evaluable lesion; * Willingness to participate in multidisciplinary consultation; * Age 18 years or older; * Sufficient tumor tissue for next-generation sequencing (NGS) with a tumor content greater than 32%; * Informed consent provided by the participant, indicating understanding of the study procedures and willingness to participate. Exclusion Criteria: * Patients with concurrent malignancies; * Pregnant patients.
💊

What it tests

  • Not listed
📍

Where

2 sites
Sun Yat'sen University Cancer Center
Guangzhou, China
Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center
Shenzhen, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy